247 related articles for article (PubMed ID: 22184390)
21. Therapeutic drug monitoring for dose individualization of Cisplatin in testicular cancer patients based upon total platinum measurement in plasma.
Salas S; Mercier C; Ciccolini J; Pourroy B; Fanciullino R; Tranchand B; Monjanel-Mouterde S; Baciuchka-Palmaro M; Dupuis C; Yang C; Balti M; Lacarelle B; Duffaud F; Durand A; Favre R
Ther Drug Monit; 2006 Aug; 28(4):532-9. PubMed ID: 16885721
[TBL] [Abstract][Full Text] [Related]
22. Determinants of ototoxicity in 451 platinum-treated Dutch survivors of childhood cancer: A DCOG late-effects study.
Clemens E; de Vries AC; Pluijm SF; Am Zehnhoff-Dinnesen A; Tissing WJ; Loonen JJ; van Dulmen-den Broeder E; Bresters D; Versluys B; Kremer LC; van der Pal HJ; van Grotel M; van den Heuvel-Eibrink MM;
Eur J Cancer; 2016 Dec; 69():77-85. PubMed ID: 27821322
[TBL] [Abstract][Full Text] [Related]
23. Long-term complications of platinum-based chemotherapy in testicular cancer survivors.
Oh JH; Baum DD; Pham S; Cox M; Nguyen ST; Ensor J; Chen I
Med Oncol; 2007; 24(2):175-81. PubMed ID: 17848741
[TBL] [Abstract][Full Text] [Related]
24. Ototoxicity and Platinum Uptake Following Cyclic Administration of Platinum-Based Chemotherapeutic Agents.
Gersten BK; Fitzgerald TS; Fernandez KA; Cunningham LL
J Assoc Res Otolaryngol; 2020 Aug; 21(4):303-321. PubMed ID: 32583132
[TBL] [Abstract][Full Text] [Related]
25. Cisplatin-induced long-term hearing impairment is associated with specific glutathione s-transferase genotypes in testicular cancer survivors.
Oldenburg J; Kraggerud SM; Cvancarova M; Lothe RA; Fossa SD
J Clin Oncol; 2007 Feb; 25(6):708-14. PubMed ID: 17228018
[TBL] [Abstract][Full Text] [Related]
26. Continuous or repeated prolonged cisplatin infusions in children: a prospective study on ototoxicity, platinum concentrations, and standard serum parameters.
Lanvers-Kaminsky C; Krefeld B; Dinnesen AG; Deuster D; Seifert E; Würthwein G; Jaehde U; Pieck AC; Boos J
Pediatr Blood Cancer; 2006 Aug; 47(2):183-93. PubMed ID: 16302218
[TBL] [Abstract][Full Text] [Related]
27. Long-term neurotoxicity and quality of life in testicular cancer survivors-a nationwide cohort study.
Lauritsen J; Bandak M; Kreiberg M; Skøtt JW; Wagner T; Rosenvilde JJ; Dysager L; Agerbæk M; Daugaard G
J Cancer Surviv; 2021 Aug; 15(4):509-517. PubMed ID: 32978721
[TBL] [Abstract][Full Text] [Related]
28. Circulating plasma platinum more than 10 years after cisplatin treatment for testicular cancer.
Gietema JA; Meinardi MT; Messerschmidt J; Gelevert T; Alt F; Uges DR; Sleijfer DT
Lancet; 2000 Mar; 355(9209):1075-6. PubMed ID: 10744098
[TBL] [Abstract][Full Text] [Related]
29. Usefulness of current candidate genetic markers to identify childhood cancer patients at risk for platinum-induced ototoxicity: Results of the European PanCareLIFE cohort study.
Langer T; Clemens E; Broer L; Maier L; Uitterlinden AG; de Vries ACH; van Grotel M; Pluijm SFM; Binder H; Mayer B; von dem Knesebeck A; Byrne J; van Dulmen-den Broeder E; Crocco M; Grabow D; Kaatsch P; Kaiser M; Spix C; Kenborg L; Winther JF; Rechnitzer C; Hasle H; Kepak T; van der Kooi AF; Kremer LC; Kruseova J; Bielack S; Sorg B; Hecker-Nolting S; Kuehni CE; Ansari M; Kompis M; van der Pal H; Parfitt R; Deuster D; Matulat P; Tillmanns A; Tissing WJE; Beck JD; Elsner S; Am Zehnhoff-Dinnesen A; van den Heuvel-Eibrink MM; Zolk O;
Eur J Cancer; 2020 Oct; 138():212-224. PubMed ID: 32905960
[TBL] [Abstract][Full Text] [Related]
30. Evaluation of long-term toxicity after chemotherapy for testicular cancer.
Bokemeyer C; Berger CC; Kuczyk MA; Schmoll HJ
J Clin Oncol; 1996 Nov; 14(11):2923-32. PubMed ID: 8918489
[TBL] [Abstract][Full Text] [Related]
31. Adverse health outcomes and global quality of life in long-term testicular cancer survivors: a longitudinal 30-year perspective.
Fosså SD; Haugnes HS; Dahl AA; Kiserud CE; Fosså A; Skalleberg J; Myklebust TÅ
Ann Oncol; 2023 Dec; 34(12):1165-1174. PubMed ID: 37739265
[TBL] [Abstract][Full Text] [Related]
32. Serum creatinine and cholesterol levels of testicular cancer patients in long-term follow up.
Hisamatsu E; Kawai K; Hinotsu S; Miyanaga N; Shimazui T; Akaza H
Int J Urol; 2005 Aug; 12(8):751-6. PubMed ID: 16174050
[TBL] [Abstract][Full Text] [Related]
33. Treatment-specific risks of second malignancies and cardiovascular disease in 5-year survivors of testicular cancer.
van den Belt-Dusebout AW; de Wit R; Gietema JA; Horenblas S; Louwman MW; Ribot JG; Hoekstra HJ; Ouwens GM; Aleman BM; van Leeuwen FE
J Clin Oncol; 2007 Oct; 25(28):4370-8. PubMed ID: 17906202
[TBL] [Abstract][Full Text] [Related]
34. Cardiovascular events in survivors of high-dose chemotherapy for germ cell tumors.
Ishioka J; Fujii Y; Kageyama Y; Fukuda H; Higashi Y; Kihara K
Int J Urol; 2008 Jul; 15(7):642-5. PubMed ID: 18643784
[TBL] [Abstract][Full Text] [Related]
35. Cisplatin treatment of testicular cancer patients introduces long-term changes in the epigenome.
Bucher-Johannessen C; Page CM; Haugen TB; Wojewodzic MW; Fosså SD; Grotmol T; Haugnes HS; Rounge TB
Clin Epigenetics; 2019 Dec; 11(1):179. PubMed ID: 31796056
[TBL] [Abstract][Full Text] [Related]
36. [Long-term side effects of chemotherapy for testicular cancer].
Kawai K
Gan To Kagaku Ryoho; 2002 Jul; 29(7):1300-5. PubMed ID: 12146015
[TBL] [Abstract][Full Text] [Related]
37. Longitudinal serum testosterone, luteinizing hormone, and follicle-stimulating hormone levels in a population-based sample of long-term testicular cancer survivors.
Sprauten M; Brydøy M; Haugnes HS; Cvancarova M; Bjøro T; Bjerner J; Fosså SD; Oldenburg J
J Clin Oncol; 2014 Feb; 32(6):571-8. PubMed ID: 24419125
[TBL] [Abstract][Full Text] [Related]
38. [Detection of ototoxic effect of cisplatin with otoacoustic emission in testicular cancer patients].
Biró K
Magy Onkol; 2009 Sep; 53(3):279-83. PubMed ID: 19793694
[TBL] [Abstract][Full Text] [Related]
39. Platinum exposure and cause-specific mortality among patients with testicular cancer.
Groot HJ; van Leeuwen FE; Lubberts S; Horenblas S; de Wit R; Witjes JA; Groenewegen G; Poortmans PM; Hulshof MCCM; Meijer OWM; de Jong IJ; van den Berg HA; Smilde TJ; Vanneste BGL; Aarts MJB; Jóźwiak K; van den Belt-Dusebout AW; Gietema JA; Schaapveld M
Cancer; 2020 Feb; 126(3):628-639. PubMed ID: 31730712
[TBL] [Abstract][Full Text] [Related]
40. Medical interventions for the prevention of platinum-induced hearing loss in children with cancer.
van As JW; van den Berg H; van Dalen EC
Cochrane Database Syst Rev; 2019 May; 5(5):CD009219. PubMed ID: 31063591
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
